The Artificial Intelligence in Oncology market is anticipated to grow at a CAGR of 54% claims Roots Analysis

The success of currently employed artificial intelligence (AI) solutions has encouraged researchers to explore the potential of such technologies in the healthcare sector, with its prime focus being oncology, to enable the treatment of several prevalent malignancies.

London

Roots Analysis has announced the addition of “Artificial Intelligence in Oncology Market, 2022-2035” report to its list of offerings.

Several AI technologies demonstrating the potential to diagnose precancerous lesions are expected to be capable of reducing mortality rates by improving detection accuracy, speed and providing assistance in clinical decision-making. This is further expected to result in better clinical outcomes. Overall, this domain is anticipated to gain significant traction, in the foreseen future.

Key Market Insights

Over 76 companies claim to be engaged in the development of AI in oncology software solutions
The AI in diagnostics market is dominated by companies based in North America, primarily in the US; of these, majority were established post 2010 and are small firms. Majority of the companies in this domain offer software solutions to hospitals (52%).

Nearly 2,770 patents have been filed / granted for AI based software solutions targeting oncology
Reflecting the increasing research efforts of several industry players engaged in this domain, around 60% of the patents focused on the AI in oncology domain were filed / granted in North America, primarily in the US. It is also worth noting that the maximum patents were filed (69%) by non-academic players.

Partnership activity in this market has increased at a CAGR of 36% over the past five years
Technology integration agreements emerged as the most popular type of partnership model adopted by AI in oncology software solution providers, representing over 30% of the total instances. It is worth mentioning that 41% of the partnerships in this domain were inked in 2021.

USD 5.9+ billion has been invested by both private and public investors, since 2017
The maximum funding amount was raised through venture capital (66%), grants (11%) and seed funding (8%), during the period 2017-2022. Interestingly, around 86% of the funding instances were reported by players based in the US.

Europe is anticipated to capture over 30% of the global market share in 2035
In terms of cancer, the AI in oncology market for solid malignancies is likely to capture the maximum share (33%), followed by the share captured by breast cancer (30%), and this trend is unlikely to change in the foreseen future as well.

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/....reports/ai-in-oncolo

Key Questions Answered
 Who are the leading players engaged in the development of AI in oncology-based software solutions?
 Which type of end-users are primarily employing AI in oncology-based software solutions in their regular workflow?
 What kind of partnership models are most commonly being adopted by stakeholders engaged in this domain?
 What is the trend for capital investments in this domain?
 What are the key strategies that can be implemented by emerging players / start-ups to enter into this highly competitive market?
 What is the focus area of big pharma players in this domain?
 Which companies are actively filing patents to drive innovation in the field of AI in oncology?
 What are the key challenges associated within this domain?

The financial opportunity within the AI in oncology market has been analyzed across the following segments:
 Type of Cancer
 Solid Malignancies
 Breast Cancer
 Lung Cancer
 Prostate Cancer
 Colorectal Cancer
 Brain Tumor
 Others

 Type of End-User
 Hospitals
 Pharma Companies
 Research Institutes
 Others


 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Rest of the world

The opinions and insights presented in the report were influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:
 Jon DeVries (Chief Executive Officer, Mirada Medical)
 Piotr Krajewski (Chief Executive Officer, CancerCenter.AI)
 Christian Vestergaard Kaltoft (Chief Executive Officer, Visiopharm)
 David Wilson (Vice President, Marketing and Communications, Enlitic)
 Emily Salerno (Commercial Strategy and Operations Lead, Nucleai)

The research includes detailed list of platforms being developed by key players (some of them are listed below); the report features an overview of the platform, details related to the AI technology employed, oncological indication targeted and information related to the type of platform (cloud-based, on-site).
 Ibex Medical Analytics
 Niramai
 Optellum
 Tempus Labs
 Paige
 Kheiron Medical Technologies

For additional details, please visit https://www.rootsanalysis.com/....reports/ai-in-oncolo or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/compa....ny/roots-analysis/my
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/

The precision medicine software developers market is projected to grow at an annualized rate of 30%, till 2032, claims Roots Analysis

Given their ability to cater to the existing unmet needs in the healthcare sector, various industry stakeholders have made investments for the development and implementation of precision medicine software applications for diagnosis, analysis and treatment of a range of disorders.

Roots Analysis has announced the addition of “Precision Medicine Software Market 2021-2032” report to its list of offerings.

Conventional methods being used for the treatment of various disease indications are fraught with several challenges, including inefficiency of reporting any medical symptom / condition at the initial stage, frequent visits to hospitals, the one-size-fits-all approach. These bottlenecks have encouraged healthcare professionals to shift their attention towards the use of precision medicine software applications.

Key Market Insights

125+ precision medicine software applications are currently available / under development
This segment of the industry is dominated by the presence of small players 50 employees), which represent nearly 60% of the contemporary landscape. Further, about 75% software application developers are presently based in North America. In addition, around 90% of these applications are based on cloud.

Around 50% of software applications are intended for the treatment of oncological disorders
Presently, several precision medicine software applications are intended for diagnosis, analysis and / or treatment of oncological disorders. Other popular therapeutic areas being targeted by such software applications include neurological disorders (13%) and cardiovascular disorders (11%).

Patents filed related to precision medicine software applications, increased at a CAGR of 57%
Of the total, around 80% of the patents were filed as applications, followed by granted patents. It is worth mentioning that most of the patents (55%) were filed / granted in North America. Further, 68% of the total active patents were filed in this region, during the period 2018-2021.

Partnership activity has grown at an annualized rate of over 72%, between 2018 and 2020
Maximum number of partnerships were established in 2020, indicating the rising interest of stakeholders in this domain. Service agreements emerged as the most common type of partnership model adopted by players engaged in this domain, representing about 40% of the total number of instances.

About USD 2.4 billion has been invested by both public and private investors in this field
Funding activity in this domain has increased at a CAGR of 52%, during the period 2018-2020. Around 44% of the total amount invested was raised through venture funding rounds. In addition, majority of the funding instances (35) were focused on business development.

~50% market share is captured by software applications targeting oncological disorders, in 2022
In the foreseen future, the market opportunity is likely to be distributed amongst different end-users. Among key geographical regions, application developers based in Europe are anticipated to contribute the maximum (72.5%) to the overall market, followed by those having headquarters in North America (20.4%).

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/....reports/precision-me

Key Questions Answered
 Who are the leading players engaged in the development of precision medicine software applications?
 Which platform is more likely to reach the market in the near future?
 Which therapeutic area is primarily being targeted by precision medicine software?
 What kind of partnership models are most commonly adopted by industry stakeholders?
 Who are the key investors in this domain?
 What are the different types of data being handled by precision medicine software developers?
 How is the current and future opportunity likely to be distributed across key market segments?

The financial opportunity associated with the precision medicine software developers’ market has been analyzed across the following segments:
 Therapeutic Area
 Oncological Disorders
 Neurological Disorders
 Cardiovascular Disorders
 Metabolic Disorders

 Types of End-Users
 Hospitals
 Healthcare Providers
 Pharma and Biotech Companies

 Geographical Area
 North America
 Europe
 Asia-Pacific and Rest of the World


The research includes detailed profiles of 10+ precision medicine software applications being developed by key players (listed below); each profile features an overview of the developer, details related to recent developments and an informed future outlook.
 AceTech
 Ariel Precision Medicine
 C2i Genomics
 Genedata
 Inspirata
 IQVIA
 Fabric Genomics
 GenomOncology
 Human Longevity
 SOPHiA GENETICS
 Syapse

For additional details, please visit
https://www.rootsanalysis.com/....reports/precision-me or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/compa....ny/roots-analysis/my
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/

MEDICAL DEVICE DEVELOPERS HAVE BEEN COMPELLED TO OUTSOURCE THEIR MANUFACTURING OPERATIONS TO CONTRACT SERVICE PROVIDERS

The in-house development of peptide API requires necessary expertise and capabilities, including design, construction and maintenance of a facility which demands significant capital investments. Therefore, several small drug developers and, at times, certain pharma giants as well, have started outsourcing their manufacturing operations to contract service providers.

Over the years, the popularity of biologics has led to an evident shift in the focus of pharmaceutical companies, from traditional interventions towards more complex and advanced pharmacological interventions, such as peptide therapeutics. Since the discovery of insulin, the peptide therapeutics market has evolved significantly. The increasing demand for companies capable of offering manufacturing and, in certain cases, development services to biopharmaceutical players has resulted in the establishment of several CMOs. Most of these contract service providers have profound experience in niche and emerging areas. The innate expertise and availability of the required capabilities and infrastructure enables CMOs to effectively fulfil the requirements of their clients, eliminate costly oversights and, thereby, reduce chances of failure. As pharma companies resume full-scale operation after the COVID-19 outbreak, the demand for large-scale peptide therapeutics contract API manufacturing is expected to increase significantly.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/305/request-

In fact, drug developers are actively collaborating with CMOs that offer improved technology platforms to increase the bioavailability of peptide drugs and enhance the efficacy of the production process. The aforementioned factors are likely to drive growth of the contract manufacturing and provide lucrative opportunities to CMOs in the near future. Presently, XX% of the total capacity is available with contract manufacturers catering to the needs for commercial scale operations. Further, majority (XX%) of the peptide API contract manufacturing capacity is installed in facilities based in Europe. However, we believe that, in order to cope up with the increasing demand and maintain a competitive advantage, CMOs should further enhance their existing capabilities and capacities, as well as adopt innovative and efficient production technologies.

For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/compa....ny/roots-analysis/my
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/

Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings.

The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers.
For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen

Roots Analysis has announced the addition of the “Cell Invasion and Migration Assays Market, 2022–2035” report to its list of offerings.
Owing to several advantages offered by cell invasion and migration assays in analyzing and quantifying cellular mechanisms, industry stakeholders have undertaken numerous R&D initiatives focused on exploiting the use of such assays to expediate discovery timelines and optimize the total development cost.

For additional details, please visit
https://www.rootsanalysis.com/....reports/cell-invasio